

NEW GLYCOSPHINGOLIPIDS FROM MARINE ORGANISMS

S. Hirsch and Y. Kashman*

Sackler Faculty of Exact Sciences, School of Chemistry
Tel Aviv University, Ramat Aviv 69978, ISRAEL

(Received in UK 3 April 1989)

Abstract - The structure of several ceramides and cerebroside, from three marine sponges and a soft coral collected in the Red Sea, are reported. Specifically, the structure determination of ptiloceramide, halicerebroside A and ampicerebroside B-F was achieved following suitable degradations and NMR measurements.

The first recognition of glycolipids in a variety of marine invertebrates came in the early 1970's.¹ It was suggested that these glycolipids contain free and acylated cerebroside-like lipids. At the same time Karlsson² determined the structure of a cerebroside isolated from the sea star *Asterias rubens*, and it has been shown that the latter compound has a more complex structure than the relatively simple brain cerebroside.³ However, very few reports on the exact structures of other marine glycosphingolipids have been made until most recently.⁴⁻⁷

The latter reports of the isolation and characterization of new glycosphingolipids from the sea anemone *Anemona sulcata*,⁴ the starfish *Acanthaster planci*,⁵ the sponge *Chondropsis* sp.⁶ and from the sea hare *Aplysia kuroda*⁷ have led us to publish our results on related compounds.

Spectroscopic (mainly NMR) as well as chromatographic methods¹ have shown that quite a few of the marine organisms we have investigated (sponges, tunicates and soft corals) contain ceramides and cerebroside. Thus, a sphingosine derivative (**1**, Fig.1) was separated from *Heteroxenia gardaquensis* collected at the entrance to the Gulf of Suez.⁸ This compound was found to be erythro-docosaphinga-4,8-dienine, identical with the most recently reported metabolite of *Anemona sulcata*.⁴

Another ceramide was isolated from *Ptilocaulis spiculifer*. After several chromatographies on Sephadex LH-20 eluted with hexane-chloroform 3:7 or chloroform-methanol 1:1, we isolated from the ethyl acetate extract of this sponge a fraction exhibiting antifungal activity (*Candida albicans*, MIC=12.5 µg/ml). Final purification of the active components, named ptiloceramides (**2a**), was achieved following acetylation and chromatography of the tetraacetyl derivatives (**2b**) on a silica gel column. This mixture of tetraacetyl ptiloceramides (**2b**) exhibited in the mass spectra (DCI, isobutane) a series of peaks at m/z: 852, 838, 824, 810 and 796(MH⁺), suggesting five homologues (Fig.1) which were not further separated.

The sequence of the C-1 to C-5 moiety in **2b**, which includes three hydroxyls and an amide functionality (Fig.1), was established by a COSY experiment which correlated all the corresponding protons, including the NH signal (δ_{H} 6.60-7.40ppm; a region which is characteristic for the NH in glycosphingolipids).

The multiplicity and chemical shift of the fourth CHOAc group (δ_H 5.11m; δ_C 74.0d) suggested it to be α to the amide carbonyl (on C-2"). Indeed, acid hydrolysis of ptiloceramide (**2a**, 10% HCl in MeOH) afforded a mixture of three n-C₂₃-C₂₅ α -hydroxy methylesters which were identified by their mass spectrum (see Experimental). Obtaining of normal α -hydroxy esters was in full agreement with the isopropyl terminus on the isolated sphingosine portion (C₁-C₁₇(19)).⁹ As no separation of the homologues has been undertaken, the m to n combinations were not disclosed. Worth mentioning is the structure of cerebroside **3**, isolated by Endo from the sponge *Chondropsis* sp.⁶, which also possesses the iso-propyl terminus as compound **2a** (Fig.1).

Another sponge we have investigated, *Haliclona* sp., was found to be very sticky. The compound responsible for this feature was tracked down to the CH₂Cl₂-MeOH 95:5 extract which exhibited mild antitumor activity against P388 leukemia cells (84% inhibition in a concentration of 20 μ g/ml). Almost 10% of this methanolic dichloromethane extract was composed of a single compound designated halicerebroside A (**4a**, Scheme 1). Compound **4a**, which gives a highly viscous solution in chloroform, was purified on Sephadex LH-20 and TSK HW-40 columns, both eluted with chloroform-methanol.





Figure 1

For NMR measurements the heptaacetate of **4a** (**4b**) was prepared under the usual conditions (Ac₂O/Pyr., rt overnight). 2D-NMR studies of **4b**, including a COSY¹⁰, a RELAY¹¹ (Fig. 2) and a one bond HETCOR¹² experiments, proposed the following partial structures (**a-c**):



The following correlations have been observed in a COSY experiment; for **a** between: 1'/2', 2'/3', 3'/4', 4'/5' & 5'/6'; for **b** between: 1/2, 2/NH&3, 3/4, 4/5, 5/6, 6/7, 7/8,

8/9 & 17/18 and for \underline{c} between: 2"/3", 3"/4", 21"/22"; and in a RELAY experiment we observed the additional following correlations between protons: for \underline{a} : 1'/3', 2'/4', 3'/5', 4'/6' and for \underline{b} : 1/3, 3/5, 5/7, 6/8 (see Fig.2).

Reductive ozonolysis of $\underline{4b}$ (O_3 , $NaBH_4$) furnished n-1-dodecanol ($\underline{5}$) and compound $\underline{6}$ (Scheme 1). The n-dodecanol ($\underline{5}$) confirmed the 6(7) position of the double bond, in $\underline{4}$, as proposed in sub-structure \underline{b} , and the complete NMR analysis of segment $\underline{6}$ (see Experimental) determined the β -glucosyl ceramide structure.

Acid hydrolysis of $\underline{4a}$ (4 hrs reflux in 10% methanolic HCl) afforded three compounds: $CH_3(CH_2)_{19}CH(OH)CO_2CH_3$, methyl glucopyranoside¹⁴ and sphingosine $\underline{7}$ (Scheme 1). The sugar portion was chromatographically purified after acetylation and yielded mainly compound $\underline{8a}$. Alkaline removal of the acetate groups (10% NH_4OH in MeOH), followed by acidic cleavage of the methyl glycoside, yielded D-glucose, $[\alpha]_D^{+50}$ (lit. $+52^\circ$)⁷. The structure of the sphingosine, erythro-octadeca-sphinga-6-ene ($\underline{7}$), was established by its NMR spectrum and the fragmentations in the mass spectrum (see Experimental) and was found to be in full accordance with the structure of compound $\underline{6}$. Compound $\underline{4a}$ has many similarities with $\underline{3}$ (Fig.1) and also with the most recently reported acanthacerebrosides.⁵





Figure 2. Partial RELAY¹¹ spectrum of compound $\underline{4b}$ in d_6 -acetone.

Another very sticky sponge (immediately after being taken out of the water) is *Amphimedon viridis*. As with the *Haliclona* sp., the methanolic-chloroform extract afforded a highly viscous mixture, responsible for the stickiness. To facilitate the separation of



this mixture and for NMR structure elucidation, the crude extract was acetylated and submitted to repeated chromatographies on Sephadex LH-20 and silica gel columns.

The last two columns were found to be superior to reverse phase, cyano and amino bonded silica columns which failed to separate the mixture. Out of five acetylated compounds, designated amphicerebrosides B-F (compounds 9b-13b, Fig.3), only one (11b) was obtained in a pure state. All the others could only be obtained in an enriched form. However, by comparing and subtracting the NMR spectra of the mixtures, individual spectroscopic data were obtained and their structure elucidated.

Comparison of the NMR data of acetylated amphicerebroside B (9b, Table 1) with that of hepta-acetyl halicerebroside A (4b) clearly pointed to the identity of the two long chains (C₁"-C₂₂" and C₃-C₂₀) in the two compounds and to differences in the sugar moiety. The presence of an amino-monosaccharide, suggested by the chemical shifts¹³ of the latter moiety, was confirmed following acetylation of the acidic hydrolysis product 16a, *vide infra*, with Ac₂O in MeOH to give the mono acetamide.

Acid hydrolysis of 9b (10% HCl in MeOH, 4hr) afforded methyl 2-amino-2-deoxy-glucofuranoside (16a), compound 14 and methyl α -hydroxy-doeicosanoate (Fig.4). As before, the monosaccharide was purified after acetylation (see Experimental). The NMR spectrum of 9b clearly pointed out the β -anomeric linkage of the glycoside.

Amphicerebroside C heptaacetate (10b) differs from 9b only in the location of the double bond which is here in the 5(6) rather than the 6(7) position in 9b. This was determined by the NMR spectra which included a COSY experiment.

Compound **11b** was, as mentioned above, the only compound that was completely purified. Confirmation of its structure, the dihydro derivative of either **9b** or **10b**, was obtained upon catalytic hydrogenation of the latter compounds to afford **11b**.

Table 1. ^1H and ^{13}C NMR data of ampicerebroside B heptaacetate (**9b**)^a.

C No	δ_{C} (m)	$\delta_{\text{H}}^{\text{b}}$ (m, J in Hz)	C No	δ_{C} (m)	$\delta_{\text{H}}^{\text{b}}$ (m, J in Hz)
1	66.8t	3.77 (m), 3.67 (m)	3"-21"	29.5t ^d	1.30 (brs)d
2	47.4d	4.36 (m)	22"	13.3q	0.86 (t, J=7.0)
3	68.7d	5.07 (t, J=9.3)	1'	99.7d	4.78 (d, J=8.3)
4	72.3d	4.92 (dt, J=9.3,3.8)	2'	54.9d	3.69 (m)
5	36.5t	2.00 ^c	3'	71.9d	5.26 (t, J=9.8)
6	124.1d	5.31 (dt, J=14.1,8.3)	4'	71.9d	5.04 (m)
7	134.5d	5.45 (dt, J=14.1,7.6)	5'	71.5d	3.73 (ddd, J=9.3,4.9 2.4)
8	32.4d	2.02 ^c			
9-17	29.5t ^d	1.30 (brs) ^d	6'	62.0t	4.25 (dd, J=9.4,4.9)
18	22.5d	1.50 (m)			4.12 (dd, J=9.4,2.4)
19,20	22.5q(x2)	0.85 (d, J=6.6)	NH-2		6.68 (d, J=9.0)
C=O	171.5s(x7)		NH-2'		6.09 (d, J=7.5)
2"	72.3d	4.90 (m)			

a. The compound was dissolved in CDCl_3 ; 360.13 MHz for ^1H and 90.53 MHz for ^{13}C .

b. Correlations between protons and carbons were established from a CHCORR experiment (J=140Hz). c. Overlapping with the methyls of the acetate groups.

d. Several methylenes of a long chain.

The NMR spectra of compounds **12b** and **13b**, ampicerebrosides E & F heptaacetates, pointed to the same structures as compounds **9b** and **10b** respectively, except for the anomeric C-O bond which, according to the 4.9Hz coupling constant of H-1' with H-2', has to be of the α configuration in ampicerebrosides E and F (**12** & **13**). Acidic hydrolysis in methanol and selective acetylation of the amine moiety in the sugar molecule furnished methyl 2-acetamido-2-deoxy-D-glucopyranoside¹⁴.

The five heptaacetyl ampicerebrosides, **9b-13b**, exhibited low antifungal activity against *C.albicans*.

After identifying the ampicerebrosides B-F from *Amphimedon viridis* we are fairly convinced that the same compounds are also present in small amounts in the extract of the *Halictona sp.* sponge.

Acknowledgment: Harbor Branch Oceanographic Institution - Biomedical Marine Research, for financial support and biotesting of the compounds, Dr. P. McCarthy from H.B.O.I. for the antifungal tests, Dr. M. Cojokaro, Bar Ilan Univ., for MS-measurements and Mrs. Y. Abudi for the technical assistance.




Figure 3. The structures of ampicerebrosides B-F (9-13).




Figure 4. Degradation products of ampicerebrosides B-F

Experimental: For general information see Tetrahedron **43** (14), 3257 (1987).

Ptiloceramide 2a was isolated from *Ptilocaulis spiculifer* collected in the Bahamas. The sponge (50gr) was freeze-dried, ground and extracted with ethyl acetate (2 x 250 ml). This extract was evaporated *in vacuo* (2gr) and then chromatographed on a Sephadex LH-20 column with hexane-chloroform 3:7 or chloroform-methanol 1:1. The bio-active fractions (*in vitro* activity, against *Candida albicans* up to MIC = 12.5 μ g/ml) were combined (150mg) and

acetylated with a mixture of pyridine-Ac₂O (1:1, 10ml) at rt overnight. After evaporation the residue was chromatographed on a silica gel column, eluted with petroleum ether/ethyl acetate to afford **2b** (100mg). **Tetraacetyl ptiloceramide 2b**: an oil, CIMS m/z 852, 838, 824, 810 and 796 (MH⁺); ν_{\max} (CHCl₃): 3500-3300, 2940, 1740, 1608, 1220cm⁻¹; δ_{H} (CDCl₃): 6.64d(NH, J=9.0), 5.11m(H-3, H-2'), 4.95dt(H-4, J=9.8, 3.2), 4.44m(H-2), 4.35dd(H-1, J=11.7, 6.4), 4.02dd(H-1, J=11.7), 2.19s (Ac-2'), 2.09s, 2.06s, 2.03s(3Ac), 1.82m(H-3'), 1.65m(2H, H-5), 1.50m(H-isopropyl), 1.30m(H-3'), 1.29 (long chain), 0.88t(3H, J=6.3), 0.85d(6H, J=6.6); δ_{C} (CDCl₃, C No.): 181.3s, 171.2s, 170.8s, 169.9s(X2), 74.0d(2'), 72.7d(4), 72.5d(3), 62.4t(1), 47.9d(2), 31.9t(3'), 31.8t(5), 29.2t (the long chain), 28.7t, 25.5t, 24.9t, 22.6q, 22.6d, 20.9q(X4), 14.0q.

Isolation of halicerebroside A (4a): Freeze-dried *Haliclona* sp. (40gr), collected in the straits of the Gulf of Eilat (the Red Sea) in July 1986, was ground and extracted with chloroform and chloroform/methanol 95:5. Evaporation of the 5% methanolic extract yielded a viscous dark oil (2.4gr). Repeated chromatographies on Sephadex LH-20 and TSK HW-40 columns, both prepared and eluted with chloroform/methanol 1:1, afforded halicerebroside A (**4a**, 300mg). Compound **4a**: a sticky oil, CIMS m/z 816 (MH⁺, Methane); ν_{\max} (CHCl₃): 3350, 2920, 1670, 1210, 1070 cm⁻¹; δ_{H} (CDCl₃+CD₃OD): 7.66d(1H, J=8.5), 5.41dt(2H, J=15.2, 6.5), 4.23d(1H, J=7.6), 4.12-3.22m(11H, the sugar and ceramide protons), 2.26dd(1H, J=7.3, 3.0), 2.08m(1H), 1.92t(2H, J=6.2), 1.71m(1H), 1.50m(1H), 1.18 (the long chain), 0.80t(6H, J=6.5); δ_{C} (CDCl₃+CD₃OD): 175.3s, 133.5d, 125.2d, 102.9d, 75.7d(X2), 72.8d, 71.4d, 71.1d, 69.3d(X2), 68.1d, 60.7d, 49.7d, 35.2t, 33.8t.

Isolation of amphicerebroside B-F (9a-13a): Freeze-dried *Amphimedon viridis*, collected in the straits of the Gulf of Eilat in July 1982 (110gr), was ground and extracted with hot chloroform and chloroform/methanol 75:25. The latter extract (5.5gr) was acetylated (as described for **2a**) and then purified by repeated chromatographies on Sephadex LH-20 eluted with chloroform/petroleum ether 7:3 and on Silica gel columns eluted with petroleum ether/10-30% acetone, to afford heptaacetyl amphicerebroside B-F (**9b-13b**). The pairs of heptaacetyl amphicerebroside **9b** & **10b** and **12b** & **13b** were eluted together as 1:1 mixtures, followed by compound **11** (Rf=0.35, 0.34 and 0.33, Silica gel, petroleum ether/acetone 3:1, visualized with I₂, respectively).

Amphicerebroside B heptaacetate (9b): an amorphous powder, ν_{\max} (CHCl₃): 3400, 2900, 1740, 1670, 1250, 1050 cm⁻¹; ¹H and ¹³C NMR: Table 1.

Amphicerebroside C heptaacetate (10b): an amorphous powder, ν_{\max} (CHCl₃): 3400, 2900, 1740, 1670, 1250, 1050 cm⁻¹; δ_{H} (CDCl₃): 6.66d(NH-2, J=9.1), 5.78dd(H-6, J=15.5, 7.4), 5.36dd(H-5, J=15.5, 7.0), 4.81d(H-1', J=8.2), 4.35m(H-4), 2.15m(H-7); δ_{C} (CDCl₃, C No.): 136.6d(6), 128.8d(5), 99.7d(1'), 86.9d(4), 32.2t(7), 32.1t, 31.2t, 29.0t (long chain), 24.6t, 22.0t, 13.3q(X2); all the other resonance lines are identical with those of compound **9b** (Table 1).

Amphicerebroside D heptaacetate (11b): an amorphous powder, ν_{\max} (CHCl₃): 3350, 2910, 1740, 1670, 1250 cm⁻¹; δ_{H} (CDCl₃): 1.65m(H-5), 1.30brs(H-6, overlaps with the long chain

protons); δ_C (CDCl₃, C No.): 31.9t(5), 29.5t(6); all the other resonance lines are identical with those of compound **9b** (Table 1).

Amphicerebroside E heptaacetate (12b): an amorphous powder, ν_{\max} (CHCl₃): 3400, 2900, 1740, 1670, 1250, 1050 cm⁻¹; δ_H (CDCl₃): 7.22d(NH-2, J=7.0), 6.14d(NH-2', J=7.8), 5.36t(H-3', J=9.5), 4.85d(H-1', J=4.9), 3.50m(H-2'); δ_C (CDCl₃, C No.): 99.1d(1'), 72.0d(3'), 55.0d(2'), 47.9d(2); all the other resonance lines are identical with those of compound **9b** (Table 1).

Amphicerebroside F heptaacetate (13b): an amorphous powder, ν_{\max} (CHCl₃): 3400, 2900, 1740, 1670, 1250, 1050 cm⁻¹; δ_H (CDCl₃): 7.22d(NH-2, J=7.0), 6.14d(NH-2', J=7.8), 5.78dd(H-6', J=15.5, 7.4) 5.36m(H-5 and 3'), 4.85d(H-1', J=4.9), 3.50m(H-2'); δ_C (CDCl₃, C No.): 136.6d(6), 128.8d(5), 99.1d(1'), 86.9d(4), 72.0d(3'), 55.0d(2'), 47.9d(2), 32.2t(7); all the other resonance lines are identical with those of compound **9b** (Table 1).

Acid hydrolysis of ptiloceramide (2a): Compound **2a**(30mg), dissolved in 10% HCl-MeOH(5ml) was refluxed for 4 hours. The solution was then neutralized with Ag₂CO₃(S), filtered, most of the MeOH evaporated and the residue extracted with ethyl acetate (2x15ml). The organic layer was dried over anhy. MgSO₄ and evaporated to dryness to yield a mixture of n- α -hydroxy methyl esters (8mg). EIMS m/e 412, 398, 384(M⁺, 28, 26 & 13%, n=22, 21, 20), 353, 339, 325(M-Ac, 17, 19, 9%).

Acetylation of compound 4a to 4b: Compound **4a** (50mg) was acetylated with Ac₂O-Pyridine 1:1 (2ml) at rt, as described for **2a** to yield compound **4b** (40mg), TLC: R_F=0.6 (Silica gel, chloroform/methanol 9:1, visualized with vanillin). ν_{\max} (CHCl₃): 3350, 2920, 1740, 1670, 1360, 1030cm⁻¹; δ_H (acetone-d₆): 7.29d(1H, NH-2, J=9.2), 5.53dt(1H, H-6, J=15.3, 6.8), 5.36dt(1H, H-7, J=15.8, 6.6), 5.26t(1H, H-3', J=9.5), 5.18dd(1H, H-3, J=8.3, 3.5), 5.08t(1H, H-2'', J=6.2), 5.04t(1H, H-4', J=9.8), 4.98dt(1H, H-4, J=9.9, 3.5), 4.88t(1H, H-2', J=8.0), 4.79d(1H, H-1', J=8.0), 4.40m(1H, H-2), 4.29dd (1H, H-6', J=12.3, 4.8), 4.14dd(1H, H-6', J=12.3, 2.4), 3.96ddd(1H, H-5', J=10.1, 4.8, 2.4), 3.92dd (1H, H-1, J=10.8, 5.6), 3.73dd(1H, H-1, J=10.8, 3.7), 2.51m(1H, H-5), 2.31m(1H, H-5), 2.11s(3H, Ac), 2.10s(3H, Ac), 2.06s(3H, Ac), 2.04s(3H, Ac), 2.01s(3H, Ac), 1.99brs(5H, Ac, H-8), 1.96s(3H, Ac), 1.83m (2H, H-3"), 1.31 (the long chain), 0.91brt(6H, J=6.5); δ_C (acetone-d₆, C No.): 168.6s(X8), 133.0d(6), 124.5d(7), 99.5d(1'), 73.1d(2"), 72.2d(4, 3'), 71.2d(3), 70.7d(2'), 67.9d(4'), 66.8t(1), 61.3t (6'), 47.6d(2), 31.9t(3"), 31.2t(8, 5), 28.5 (long chain), 19.4q (X7), 13.0q(18, 40).

Reductive ozonolysis of 4b: A saturated solution of O₃ in CH₂Cl₂(10ml) at -78°C was added to compound **4b** (45mg) in CH₂Cl₂ (1ml). After one hour, methanol (10ml) was added and the ozonide was reduced with NaBH₄ (40mg, rt, for two hours). The excess of the reagent was destroyed with acetic acid followed by water (20ml). The aq. layer was extracted with CH₂Cl₂ (3x15ml) and the combined organic layer dried over anhy. MgSO₄. The residue (42mg) was chromatographed on a silica gel column to furnish n-1-dodecanol (**5**, 5mg) and compound **6** (28mg). TLC: R_F = 0.6 and 0.4 for **5** and **6** respectively (silica gel, heptane/acetone 2:1, visualized with vanillin). **Compound 5**: an oil, CIMS m/z 185(M-1, 5%), 169(M-OH, 12%), 155(M-CH₂OH, 14%), 141(M-C₄H₅O, 5%), 71(C₅H₁₁, 100%); δ_H (CDCl₃):

3.57t(2H, J=6.6), 1.49m(2H), 1.19 (the long chain), 0.82t(3H, J=6.5). **Compound 6**: an oil, CIMS m/z 960(MH⁺, 60%), 901(M-OAc, 49%), 390(C₁₄H₁₉O₉, 100%); δ_H (CDCl₃): 7.05d(NH, J=9.2), 5.23dd(1H, J=9.2, 2.6), 5.11t(1H, J=9.5), 5.09m(3H), 4.86t(1H, J=8.0), 4.40d(1H, J=8.0), 4.23m(2H), 4.08dd(1H, J=12.3, 2.3), 3.79dd(1H, J=10.5, 2.8), 3.62m(2H), 3.55dd(1H, J=10.5, 3.4), 3.51dt(1H, J=10.3, 3.4), 2.12s(Ac), 2.01s(Ac), 2.00s(Ac), 1.97s(2Ac), 1.95s(Ac), 1.92s(Ac), 1.75m(2H), 1.18t (the long chain), 0.80t(3H, J=6.6).

Acid hydrolysis of 4a: Compound **4a** (100mg), dissolved in 10% aq. HCl/MeOH (10ml), was refluxed for four hours. Water was then added and the aq. phase extracted with ethyl acetate (3x15ml). The organic layer was dried over anhy. MgSO₄ and evaporated to furnish an oil (67mg) which was purified on a Silica gel column eluted with petroleum ether/ethyl acetate 4:1 and ethyl acetate/methanol 9:1 to afford methyl α -hydroxy-doeicosanoate (15mg) and sphingosine **7** (10mg). The aq. layer was neutralized with Ag₂CO₃(S) and filtered over celite, the solution was lyophilized and the residue acetylated, as described for **2a**. Chromatography of the product on a Silica gel column eluted with petroleum ether/ethyl acetate 1:4, mainly afforded the α -anomer **8a** (10mg). Alkaline hydrolysis of **8a**(5mg) in 10% aq. NH₄OH-MeOH(2ml, rt, overnight) followed by acid hydrolysis (10% aq. NH₄OH-MeOH (2ml, rt overnight) followed by acid hydrolysis (10% H₂SO₄, 1ml, 100°, 1hr) yielded D-glucose, $[\alpha]_D^{20} +50^\circ$ (H₂O, lit. +52°)⁷. **Methyl- α -hydroxy-doeicosanoate**: an oil, EIMS m/e 370(M⁺, 2%), 355(M-CH₃, 1%), 311(M-C₂H₃O₂, 3%); δ_H (CDCl₃): 3.29t(1H, J=7.5), 1.77m(24), 1.24(the long chain), 0.88t(3H, J=6.3). **Sphingosine 7**: an oil, DCIMS m/z 316(MH⁺), 298(M-OH, 20%), 195(M-C₄H₁₀NO₃, 10%).

Acid hydrolysis of a mixture of 9b & 10b: A mixture of compounds **9b** & **10b** (70mg) was dissolved in a 10% aq. HCl/MeOH solution (10ml), and refluxed for four hours. Water (5ml) was then added and the aq. solution extracted with ethyl acetate (3 X 10ml) to furnish methyl- α -hydroxy-doeicosanoate (10mg) and a mixture of sphingosines **14** & **15** (8mg, in a 1:1 ratio). The aq. layer was treated with Ag₂CO₃(S), as described for **4a**, then acetylated and the residue after evaporation chromatographed on a Silica gel column eluted with ethyl acetate, to mainly afford methyl-2-acetamido-2-deoxy-3,4,6-triacetate- α -D-glucopyranoside (**16b**, 8mg). **Methyl-2-acetamido-2-deoxy-3,4,6-triacetate- α -D-glucopyranoside (16b)**: an amorphous powder, EIMS m/e 361(M⁺, 3%), 302(M-Ac, 8%), 242(M-2Ac, 37%), 199(M-C₄H₈O₂, 25%), 181(M-3Ac, 24%); δ_H (CDCl₃): 5.53d(NH-2', J=10.7), 5.30t(H-3', J=10.2), 5.11t(H-4', J=9.5), 4.61d(H-1', J=8.4), 4.31dd(H-6', J=12.3, 4.6), 4.19dd(H-6', J=12.3, 2.4), 3.91dt(H-2', J=10.2, 8.6), 3.73ddd (H-5', J=9.5, 4.6, 2.4), 3.53s, 2.20s, 2.15s, 2.10s, 2.05s. **Alkaline hydrolysis of 16b**: Compound **16b** in 10%NH₄OH-MeOH (2ml) at rt, overnight, afforded **16a** (5mg). Acetylation of the amino group, with 10%Ac₂O-MeOH solution, (1ml) at rt, overnight, furnished methyl-2-acetamido-2-deoxy-D-glucopyranoside, $[\alpha]_D^{25} +114^\circ$ (H₂O, lit. + 119°)¹⁴.

Methyl- α hydroxy-doeicosanoate: an oil, EIMS m/e 370(M⁺, 2%), 355(M-CH₃, 1%), 311(M-C₂H₃O₂, 3%), δ_H (CDCl₃): 3.29t(1H, J=7.5), 1.77m(2H), 1.24 brs (the long chain), 0.88t(3H, J=6.3).

Sphingosines 14 & 15: an oil, DCI MS m/z 344(MH⁺), 326(M-OH, 10%), 300(M-C₃H₇, 5%), 223(M-C₄H₁₀NO₃, 8%).

Hydrogenation of a mixture of compounds 9b & 10b to give 11b: A mixture of **9b+10b**(12mg) dissolved in ethyl alcohol (2ml) was hydrogenated in the presence of a catalytic amount of PtO₂ at 25° for 3hrs., under 3 atm. The solvent was then evaporated to afford compound **11b**(8mg).

Hydrolysis of 11b: Hydrolysis under the same conditions as described for **9b** & **10b**, afforded methyl- α -hydroxy-doeicosanoate and sugar **16a**.

Acid hydrolysis of 12b & 13b : Hydrolysis of **12b** & **13b** under the same conditions as described for **9b** and **10b**, furnished methyl- α -hydroxy-doeicosanoate (12mg) and sphingosines **14** & **15** (9mg, in a 1:1 ratio) and upon acetylation of the aq. layer, mainly methyl-2-acetamido-2-deoxy-3,4,6-triacetate- β -D-glucopyranoside (**17b**, 8mg). Compound **17b**, EIMS m/e 361(M⁺, 3%), 302(M-Ac, 6%), 242 (M-2Ac, 37%), 181(M-3Ac, 24%); δ _H(CDCl₃): 5.72d(NH-2', J=10.3), 5.14t(H-3', J=9.6), 4.76d(H-1', J=8.4), 4.38dt(H-2', J=10.3, 3.6), 4.23dd(H-6', J=12.3, 4.5), 4.14dd(H-6', J=12.3, 2.4), 3.95ddd(H-5', J=9.6, 4.5, 2.4), 3.43s(OCH₃), 2.10-2.05s(X4). **Alkaline hydrolysis of 17b:** Compound **17b** (8mg) in 10% NH₄OH-MeOH (2ml) at rt overnight, afforded **17a** (5mg). Hydrolysis of **17a** (10% aq. H₂SO₄, 1ml, 1hr, 100°) afforded D-glucosamine. Acetylation of the amino group of **17a** (10% Ac₂O-MeOH, 1ml, rt, overnight) furnished N-acetyl-D-glucosamine, $[\alpha]_D^{25} +54^\circ$ (H₂O, lit. +55°).

References

1. V.E. Vaskovsky, E.Y. Kostetsky, V.I. Svetashev, I.G. Zhukova and G.P. Smirnova, *Biochem. Physiol.* **34**, 163 (1970).
2. K.A. Karlsson, *Chem. Phys. Lipids* **5**, 6 (1970), and L.R. Bjorkman, K.A. Karlsson, I. Pascher and B.E. Samuelsson, *Biochim. Biophys. Acta* **270**, 260 (1972).
3. H.E. Carter, W.D. Celmer, W.E.M. Lands, K.L. Mueller and H.H. Tomizawa, *J. Biol. Chem.* **206**, 613 (1954).
4. K. Chebaane and M. Guyot, *Tet. Lett.* **27**, 1495 (1986).
5. Y. Kawano, R. Higuchi, R. Isobe and T. Komori, *Liebigs Ann. Chem.* **1**, 19 (1988).
6. M. Endo, M. Nakagawa, Y. Hamamoto, *Pure and Appl. Chem.* **58**, 387 (1986).
7. S. Araki, S. Abe, S. Odoni, S. Ando, M. Fujii and M. Satake, *J. Biol. Chem.* **262**, 14141 (1987).
8. D. Green as part of MSc. thesis, Tel Aviv University, 1988.
9. K.A. Karlsson and G.A.L. Holm, *Acta Chem. Scand.* **19**, 2423 (1965).
10. A. Bax, R. Freeman and G. Morris, *J. Magn. Reson.* **42**, 164 (1981).
11. A. Bax and G. Drobny, *J. Magn. Reson.* **61**, 306 (1985).
12. A. Bax, R.H. Griffey, B.L. Hawkins, *J. Magn. Reson.* **55**, 301 (1985).
13. R.J. Ferrier and P.M. Collins, "Monosaccharide Chemistry", ch.3, pp 50-63, 1972.
14. I. Kitagawa, M. Kobayashi, Y. Okamoto, M. Yoshikawa and Y. Hamamoto, *Chem. Pharm. Bull.* **35**, 5036 (1987).